[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346246-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346246-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tumor-agnostic-drug-delivery-with-dynamic-nanohydrogels","Tumor agnostic drug delivery with dynamic nanohydrogels","","Tumor-agnostic RNA interference delivery remains limited by rapid clearance, nuclease degradation, and poor cellular membrane penetration, leaving many cancers and metastases inadequately treated. The study develops a self-agglomerating nanohydrogel (SANGs) platform that selectively localizes to tumor tissue, is efficiently internalized by cancer cells, and is agnostic to the RNAi payload. After intravenous dosing in rodent models, SANGs accumulate and are retained in primary and metastatic sites, suppressing multiple oncogene targets, sensitizing resistant tumors, and showing safety in simulated clinical use across three species.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tumor-agnostic-drug-delivery-with-dynamic-nanohydrogels/346246/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tumor-agnostic-drug-delivery-with-dynamic-nanohydrogels/346246.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study target in RNA interference therapy?","Question",{"text":63,"@type":64},"Systemic RNA interference delivery is hindered by rapid clearance, nuclease susceptibility, and limited ability to cross plasma membranes, leading to insufficient tumor localization and penetration.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the key feature of the SANGs platform reported in the article?",{"text":68,"@type":64},"SANGs are self-agglomerating nanohydrogels that preferentially localize to tumor tissue and enable durable solid-tumor delivery without direct functionalization using targeting ligands.",{"name":70,"@type":61,"acceptedAnswer":71},"How does SANGs affect tumor biology in the reported models?",{"text":72,"@type":64},"In multiple aggressive cancer models, SANGs deliver multiple RNAi payloads that suppress oncogene expression and sensitize previously resistant tumors, while remaining safe and well tolerated across three species.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346246,1790387736,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":26,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Article [https://doi.org/10.1038/s41467-025-66788-4](https://doi.org/10.1038/s41467-025-66788-4)  \nTumor agnostic drug delivery with dynamic nanohydrogels  \nReceived: 18 April 2025  \n\n| Accepted: 13 November 2025 |\n| --- |\n| |\n| Check for updates |\n\nStephen N. Housley 1,2,3,4 , Alisyn R. Bourque4,5, Lilya V. Matyunina1, Isabel A. Panicker6, Elisa Schrader Echeverri 7, Marrissa Izykowicz8, Olivia A. Herrmann 1, Sebinne Lee 1, Johana C. Arboleda9, Vida Jamali 6  \n,  \nJohn F. McDonald1, James E. Dahlman 7 & M. G. Finn 1,4,8  \nRNA interference (RNAi) holds unique potential as a clinically viable modality to pharmacologically regulate oncogenes in sequence-speciﬁc manner. However, systemic delivery ofRNAito tumors encounters myriad obstructions, and strategies to overcome such barriers have largely consisted of academic demonstrations with few approaches reaching patients. Here we report the development of a self-agglomerating nanohydrogel (SANGs) platform that selectively localizes to tumor tissue, is efﬁciently internalized by cancer cells, is agnostic to RNAi payload, and achieves functional suppression of multiple oncogene targets. After intravenous injection, SANGs preferentially accumulate and are retained in primary and metastatic loci in four aggressive cancer models in rodents. SANGs deliver multiple RNAi payloads that signiﬁcantly suppress oncogene expression and sensitize previously resistant tumors while being safe and well tolerated in simulated clinical applications across three species. We propose, and provide the ﬁrst direct evidence in support of, a mechanism featuring emergent material properties by which SANGs achieve durable solid-tumor delivery without attachment of cell-or tumor-targeting ligands. Overall, the SANGs platform is an enabling technology for RNAi-based cancer therapeutics and is poised for advanced pharmaceutical development with multiple solid-tumor indications.  \nRNA interference (RNAi) uses small interfering RNA (siRNA) and microRNA (miRNA) to silence the expression of target genes in a sequence-speciﬁc manner1,2. RNAi molecules hold unique potential as clinically viable modalities for manifold diseases3,4. Oncological indications are of particular interest because the vast majority of cancerpromoting genes are “undruggable”4. In order to reach its potential, RNAi molecules must be delivered to tumors, preferably after systemic  \ninjection. However, successful delivery of oligonucleotides is challenging due to their rapid clearance, nuclease susceptibility, and inability to traverse plasma membranes, resulting in insufﬁcient localization to, and inadequate penetration of, tumors5–7.  \nNumerous strategies have been developed to overcome these barriers, notably by incorporation of siRNA into lipid nanoparticles (LNPs), cationic polymers, or by chemical modiﬁcation7–12. While these  \n1School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA. 2Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA. 3Discovery and Developmental Therapeutics Research Program, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. 4Bioengineering, Georgia Institute of Technology, Atlanta, GA, USA. 5George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. 6School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, USA. 7Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA. 8School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA. 9Robert P. Apkarian Integrated Electron Microscopy Core, Emory University, Atlanta, GA, USA. e-mail: [nickhousley@gatech.edu](nickhousley@gatech.edu)  \nstrategies have improved delivery, trafﬁcking is poorly understood13 and adequate design rules do not yet exist14–17. For example, LN","cbCaiiMgqwQK0FXG","https://ap.wps.com/l/cbCaiiMgqwQK0FXG","pdf",4759642,"English","# Introduction\n# Results\n## SANGs synthesis","[{\"question\":\"What problem does the study target in RNA interference therapy?\",\"answer\":\"Systemic RNA interference delivery is hindered by rapid clearance, nuclease susceptibility, and limited ability to cross plasma membranes, leading to insufficient tumor localization and penetration.\"},{\"question\":\"What is the key feature of the SANGs platform reported in the article?\",\"answer\":\"SANGs are self-agglomerating nanohydrogels that preferentially localize to tumor tissue and enable durable solid-tumor delivery without direct functionalization using targeting ligands.\"},{\"question\":\"How does SANGs affect tumor biology in the reported models?\",\"answer\":\"In multiple aggressive cancer models, SANGs deliver multiple RNAi payloads that suppress oncogene expression and sensitize previously resistant tumors, while remaining safe and well tolerated across three species.\"}]","Tumor agnostic drug delivery with dynamic nanohydrogels | PDF",1790060616,48,[147,151],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/5cb9f22352795bd3fde6b1c61b434899.webp",983,1306,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/6155d1f260275ae876b88c278a02b9d4.webp",982,1304]